Large observational cohorts consistently link GLP-1 receptor agonist (GLP-1RA) exposure — drugs like semaglutide and liraglutide — to 7–30% relative risk reductions in composite obesity-related cancer incidence across diabetic and obese populations. The strongest signals appear in hepatocellular, colorectal, endometrial, ovarian, and pancreatic cancers. Preclinical evidence points to both indirect metabolic effects (weight loss, insulin sensitization) and potentially direct antitumor mechanisms via insulin/IGF-1, cAMP/PKA, PI3K/Akt/mTOR, AMPK, and NF-κB signaling pathways. Early retrospective oncology data hint at survival benefits in active cancer patients, though causality is firmly unestablished.
This review arrives at a pivotal moment: GLP-1RAs are among the most commercially dominant drug classes globally, yet their oncologic implications remain genuinely unsettled. The 7–30% observational risk reduction sounds compelling, but these figures almost certainly carry residual confounding — healthier patients who tolerate or afford these drugs differ systematically from comparators. Critically, meta-analyses of randomized controlled trials have failed to confirm a significant reduction in overall cancer incidence, and inconsistent thyroid and colorectal cancer signals introduce genuine uncertainty. The mechanistic plurality — metabolic, immunologic, direct receptor-mediated — is scientifically intriguing but also analytically messy, making it difficult to isolate which effects actually drive any population-level signal. For clinicians, the practical guidance is appropriately conservative: prescribe for approved metabolic indications, not cancer prevention. For longevity-focused adults on GLP-1RAs, emerging cancer risk data are encouraging but nowhere near conclusive. This is incremental, hypothesis-generating evidence requiring dedicated prospective trials with cancer-specific endpoints.
